Disclaimer: Whilst we always aim to provide accurate information, Recite Me uses machine translation so the translation may not be perfect and we can’t guarantee its accuracy. Myeloma UK accepts no liability for any inaccuracies resulting from the use of this translation tool. The information provided is not meant to replace the advice of your healthcare team. Find out more about this tool at reciteme.com
This year’s UK Myeloma Society Autumn Day will focus on “Incorporating Latest Developments into Clinical Practice: Diagnostics, Novel Therapies and MDT Dilemmas”.
The meeting will bring together healthcare professionals working in myeloma to explore how emerging evidence, access updates and evolving treatment options can be applied in day-to-day clinical practice.
Practical updates across diagnostics, treatment and MDT decision-making
The programme will include UK practice and access updates, highlights from IMS 2026 in Glasgow, selected IMS and EHA abstracts, and the Michael Morley Lecture on new developments in first-line treatment.
Sessions will also cover state-of-the-art diagnostics and sequencing dilemmas, with discussion around immunotherapies, bispecific antibodies, post-BCMA treatment decisions and the role of MDT decision-making in complex patient pathways.
Who should attend?
This event is aimed at healthcare professionals involved in the diagnosis, treatment and care of patients with myeloma, including doctors, nurses, pharmacists, allied health professionals and researchers.
–
